EUVIMEDEUVIMED entdecken
Open Access

Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease

Sanjay Singh iD, Tawanda Gumbo iD, Jann-Yuan Wang iD, Gunavanthi D Boorgula, Andrew Burke iD, Hung-Ling Huang, Pamela J McShane, Rodolfo Amaro-Galvez, Jane E Gross, Santosh Aryal, Scott K Heysell, Shashikant Srivastava iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sanjay Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Imipenem, Mycobacterium abscessus, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guideline-based therapy (GBT) for Mycobacterium abscessus (Mab) lung disease achieves sputum culture conversion (SCC) rates of 35%. This poor GBT efficacy is mirrored in the hollow fiber system model of Mab (HFS-Mab). While imipenem is part of GBT, its biologic effect, with or without β-lactamase inhibitors, is unproven.

Methods

We performed imipenem-relebactam minimum inhibitory concentration (MIC) in 122 Mab isolates, and an exposure-response study in the HFS-Mab using human intrapulmonary pharmacokinetics. The percentage of time that concentration persisted above the MIC (TMIC), mediating maximal effect in the HFS-Mab, was used as the exposure target for dose finding in a Monte Carlo experiment including 10 000 virtual patients. For real-world evidence, we performed a patient, intervention (imipenem), comparison (no β-lactam), and outcome (SCC) (PICO) analysis.

Results

Imipenem killed 1.32 log10 colony-forming units/mL below the day 0 level in HFS-Mab. The average target exposure for imipenem was a TMIC of 47.9% (SD, 9.77%). Infusion of 1 g every 6 hours achieved the target in >90% of virtual patients in Monte Carlo experiments. The pharmacokinetic-pharmacodynamic MIC break point was 1 mg/L. In PICO analyses, the median time to SCC was 470 days in comparators, 311 days for imipenem added on to a failing regimen, and 37 days in newly treated patients (P = .049). The odds ratio for SCC when imipenem was part of the initial regimen, versus comparators, was 12.5 (95% confidence interval, 1.47­–84.55). No patients receiving imipenem experienced treatment-limiting adverse events, compared with 2 of 7 comparators (P = .046). Middlebrook 7H9 broth MIC distribution, read at 24 hours, was better correlated with patient responses than cation-adjusted Mueller-Hinton broth.

Conclusions

Imipenem demonstrated biologic effect in the HFS-Mab and in patients. Imipenem-relebactam doses of 1 g every 6 hours are recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImipenemMycobacterium abscessusAnti-Bacterial AgentsMycobacterium Infections, NontuberculousLung DiseasesHumansMicrobial Sensitivity TestsMonte Carlo MethodMaleFemaleTreatment OutcomeAzabicyclo CompoundsSputumMiddle Aged

Stichwörter der Autor:innen

mycobacterium abscessusHollow fiber systemMonte Carlo experimentsimipenemrelebactam

Substanzen

ImipenemAnti-Bacterial AgentsrelebactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
  • Mathematical Modeling and AI Department, Praedicare, Dallas, Texas, USA.
  • Hollow Fiber System & Experimental Therapeutics Laboratories, Wet Lab Systems, Praedicare, Dallas, Texas, USA.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Faculty of Medicine, The Prince Charles Hospital Rode Rd Chermside, Queensland, Brisbane, Australia.
  • Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsuing, Taiwan.

ORCID-Profile: Sanjay Singh, Tawanda Gumbo, Jann-Yuan Wang, Andrew Burke, Shashikant Srivastava

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Singh, S., Gumbo, T., Wang, J. Y., Boorgula, G. D., Burke, A., Huang, H. L., McShane, P. J., Amaro-Galvez, R., Gross, J. E., Aryal, S., Heysell, S. K., & Srivastava, S. (2025). Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae601

Vancouver

Singh S, Gumbo T, Wang JY, Boorgula GD, Burke A, Huang HL, et al. Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae601

BibTeX
@article{Singh2025,
  author = {Singh, Sanjay and Gumbo, Tawanda and Wang, Jann-Yuan and Boorgula, Gunavanthi D and Burke, Andrew and Huang, Hung-Ling and McShane, Pamela J and Amaro-Galvez, Rodolfo and Gross, Jane E and Aryal, Santosh and Heysell, Scott K and Srivastava, Shashikant},
  title = {Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae601}
}
Kostenlos starten →